GENERAL ONCOLOGY, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
Phase 1
Recruiting
- Conditions
- BRCA1 MutationPancreatic Acinar Cell CarcinomaBreast Cancer MetastaticBRCA2 MutationPancreatic CancerMetastatic Pancreatic Ductal AdenocarcinomaBreast Cancer Stage IVAdenocarcinoma of the BreastPancreatic Ductal AdenocarcinomaMetastatic Pancreatic Cancer
- Interventions
- Drug: Vitamin B12BDevice: Autologous Hematopoietic Stem Cells
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- General Oncology, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04150042
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
News
No news found